Open AccessSwitching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
Author(s) -
Martina Ranzenigo,
Nicola Gianotti,
Laura Galli,
Andrea Poli,
Andrea Mastrángelo,
Elena Bruzzesi,
Matteo Chiurlo,
Silvia Nozza,
Simona Bossolasco,
Vincenzo Spagnuolo,
Daniela Mancusi,
Roberta Termini,
Elisabetta Carini,
Adriano Lazzarin,
Antonella Castagna
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s358976
Subject(s) - cobicistat , darunavir , regimen , medicine , tenofovir alafenamide , interquartile range , discontinuation , raltegravir , emtricitabine , reverse transcriptase inhibitor , gastroenterology , surgery , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy
The primary objective of this study was to estimate the proportion of people living with HIV (PLWH) who switched from a non-protease inhibitor (PI)-based regimen [integrase strand transfer inhibitor (InSTI)-based or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen] to darunavir, cobicistat, emtricitabine, tenofovir alafenamide (D/C/F/TAF).